Eli Lilly Agrees to Pay Approximately $700M in Zyprexa Settlement - Brown and Crouppen Poised to Assist Victims

    /24-7PressRelease/ - St. Louis, MO, June 15, 2005 - Brown and Crouppen's team of professional lawyers is pursuing claims on behalf of individuals who have taken Zyprexa, an anti-psychotic drug manufactured by Eli Lilly and Co.

Late Thursday, June 9, 2005, Lilly announced that it will settle approximately three-quarters of the liability claims stemming from claims that the label on Zyprexa medication boxes failed to provide adequate warning that the drug could put patients more at risk for developing diabetes.

Zyprexa is the brand name for olanzapine. It is considered an "atypical" antipsychotic medication used to treat Schizophrenia and Bipolar Mania. Approved by the Food and Drug Administration (FDA) in 1996, it is thought that Zyprexa works by decreasing the effects of two chemical messengers in the brain, serotonin and dopamine.

Despite evidence dating back to the 1950s that ties the use of drugs similar to Zyprexa to increased risk of diabetes, pancreatitis, hyperglycemia and other pancreas-related illnesses, Eli Lilly and Co. continues to aggressively market the drug - which represented approximately one-third of Lilly's $4.3 billion in sales in 2004.

While Eli Lilly continues to enjoy the profits from Zyprexa sales, some feel that patients continue to suffer from the known and newly discovered health risks associated with the drug.

Ron Brown, a partner with Brown and Crouppen stated, "due to the nature of the settlement, time is of the essence to preserve the victim's rights." Anyone who has, or is currently taking the drug Zyprexa and has experienced diabetes or other glucose abnormalities, should contact Brown and Crouppen today.

About Brown and Crouppen
Brown and Crouppen has been building a reputation for success with personal injury clients for over 25 years. Today, the firm is one of mid-America's largest personal injury law firms with more than 70 legal professionals and five offices throughout Missouri and Illinois. A major emphasis for Brown and Crouppen is dangerous drug litigation involving manufacturers and suppliers of unsafe drugs and products.

For additional information, please visit www.brownandcrouppen.com, www.Zyprexa-Lawyers.com or contact:

Brown and Crouppen, Attorneys at Law
Main Office
720 Olive Street
Suite 1800
St. Louis, MO 63101
[email protected]

# # #